Y. Bang

发表

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors.

D. Heo, W. H. Kim, H. Park, 2011, Journal of Clinical Oncology.

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.

Jeffrey W. Clark, S. Ou, R. Salgia, 2010 .

Postoperative chemoradiotherapy following pancreaticoduodenectomy

J. Jang, E. Chie, S. W. Kim, 2013, Strahlentherapie und Onkologie.

6569 POSTER Updated Overall Survival Data From a Phase III Study of Sunltlnlb Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET)

E. Raymond, P. Niccoli, J. Valle, 2011 .

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial

E. Raymond, A. Vinik, P. Metrakos, 2009 .

Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

A. Iafrate, A. Shaw, B. Yeap, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

F. Lordick, L. Shen, E. Kulikov, 2007 .

O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

C. Fuchs, M. Mandalà, C. Shih, 2020 .

Phase II study of low-dose paclitaxel and cisplatin as second-line therapy in 5-fluorouracil and platinum pretreated gastric cancer

D. Heo, S. Im, Keun-Wook Lee, 2005 .

HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase III trial

A. Sawaki, H. Chung, L. Shen, 2008 .

HER2 positivity in advanced gastric cancer is comparable to breast cancer

F. Lordick, A. Sawaki, Sook Ryun Park, 2007 .

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Jianming Xu, K. Yeh, A. Ohtsu, 2010 .

6584 A phase III study of CapeOx +/− lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results

Joon-Oh Park, M. Koehler, J. Hecht, 2009 .

Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer

S. Im, T. Kim, D. Oh, 2008 .

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET).

E. Raymond, C. Lombard-Bohas, P. Niccoli, 2010 .

846P PHASE III TRIAL OF SUNITINIB (SU) VERSUS PLACEBO (PBO) FOR TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS (NET): IMPACT OF SOMATOSTATIN ANALOGUE (SSA) TREATMENT ON PROGRESSION-FREE SURVIVAL (PFS)

E. Raymond, S. Faivre, D. Castellano, 2010 .

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

A. Iafrate, A. Shaw, R. Salgia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

S. C. Wang, A. Iafrate, A. Shaw, 2019 .

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.

M. Ratain, S. Ou, R. Salgia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

A. Iafrate, A. Shaw, S. Ou, 2010 .

Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2012 .

Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC)

Jae Hyun Kim, D. Heo, D. Oh, 2005 .

Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer.

D. Heo, S. Kim, Suzy Kim, 2002, International journal of radiation oncology, biology, physics.

197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

J. Tabernero, Y. Janjigian, S. Qin, 2020, Annals of Oncology.

(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer.

Y. Hamamoto, H. Chung, E. Cutsem, 2010 .

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study.

C. Fuchs, E. Van Cutsem, J. Tabernero, 2019, Annals of Oncology.

A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer

J. Kim, D. Oh, H. Ryoo, 2008 .

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.

K. Lee, Y. Bang, J. Kim, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

Z. Wainberg, M. Alsina, M. Amonkar, 2019, Annals of Oncology.